Jacobi Capital Management LLC decreased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 94.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 664 shares of the biopharmaceutical company’s stock after selling 10,759 shares during the quarter. Jacobi Capital Management LLC’s holdings in Incyte were worth $81,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of INCY. Greenleaf Trust increased its holdings in Incyte by 2.8% in the 2nd quarter. Greenleaf Trust now owns 3,358 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 93 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Incyte by 2.4% during the third quarter. Parallel Advisors LLC now owns 5,082 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 121 shares in the last quarter. Mather Group LLC. boosted its stake in shares of Incyte by 13.5% during the third quarter. Mather Group LLC. now owns 1,157 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 138 shares in the last quarter. Tema ETFs LLC grew its holdings in shares of Incyte by 5.7% during the second quarter. Tema ETFs LLC now owns 2,704 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 145 shares during the last quarter. Finally, Trust Point Inc. grew its holdings in shares of Incyte by 5.5% during the second quarter. Trust Point Inc. now owns 2,968 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 156 shares during the last quarter. Institutional investors own 96.97% of the company’s stock.
Incyte Trading Down 0.6%
NASDAQ:INCY opened at $120.27 on Tuesday. Incyte Corporation has a 12 month low of $89.25 and a 12 month high of $132.60. The stock has a market capitalization of $24.51 billion, a price-to-earnings ratio of 63.97, a PEG ratio of 4.43 and a beta of 0.78. The firm has a fifty day simple moving average of $119.05 and a two-hundred day simple moving average of $109.05.
Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.26 earnings per share. Equities analysts predict that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on INCY. Citigroup reaffirmed a “buy” rating on shares of Incyte in a research note on Monday, August 3rd. Weiss Ratings lowered shares of Incyte from a “buy (b)” rating to a “hold (c)” rating in a report on Wednesday, November 4th. Guggenheim boosted their price objective on shares of Incyte from $136.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Truist Financial increased their price objective on Incyte from $105.00 to $115.00 and gave the company a “hold” rating in a report on Wednesday, October 14th. Finally, Leerink Partners lowered their target price on Incyte from $154.00 to $150.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Eleven research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus target price of $132.86.
View Our Latest Analysis on Incyte
Insider Buying and Selling
In related news, CMO Steven Stein sold 240,193 shares of Incyte stock in a transaction on Friday, November 6th. The shares were sold at an average price of $118.39, for a total value of $28,436,449.27. Following the completion of the sale, the chief marketing officer owned 30,916 shares of the company’s stock, valued at approximately $3,660,145.24. This trade represents a 88.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of Incyte stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the sale, the insider directly owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 254,246 shares of company stock worth $30,162,968 in the last ninety days. Corporate insiders own 16.20% of the company’s stock.
Incyte Company Profile
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Further Reading
- Five stocks we like better than Incyte
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
